Homechevron_rightIndiachevron_rightPlasmaGen Biosciences
UnspecifiedIndia

PlasmaGen Biosciences Raises INR 150 Crore from ViNS Bioproducts

VCXpress Editorial Team
calendar_today12/24/2025
schedule8 min read

bolt Executive Summary

  • PlasmaGen Biosciences raised INR 150 crore in a new funding round. ViNS Bioproducts led it. HNIs, family offices, pharma entrepreneurs, and existing investors joined in.
  • View source
PlasmaGen Biosciences Raises INR 150 Crore from ViNS Bioproducts
PlasmaGen Biosciences

PlasmaGen Biosciences raised INR 150 crore in a new funding round. ViNS Bioproducts led it. HNIs, family offices, pharma entrepreneurs, and existing investors joined in.

Funding details: INR 150 crore (Unspecified)

Full Story

PlasmaGen Biosciences raised INR 150 crore. The valuation came in over INR 1,500 crore.


ViNS Bioproducts led the round. High-net-worth individuals, family offices, pharma entrepreneurs, and existing backers also put money in.


The company plans to use the funds for international growth, adding more products, and improving manufacturing and leadership.


The CEO, Vivek V Kamath, said the last year brought big changes and set the company on a fast growth path.


Founder and executive chairman Vinod Nahar said the round shows trust in the goal to build a top plasma biopharma company based in India.


PlasmaGen started in 2010. It recently started operations at a new plasma fractionation facility in Kolar near Bengaluru. The company has raised over INR 600 crore in total so far.


PlasmaGen Biosciences develops and manufactures therapies from blood plasma, like albumin and immunoglobulins. It supplies these to private hospitals and state governments across India. The company is based in Bengaluru.



Source:- The Economic Times.

Filed Under

Recommended next

View all

Stay ahead of the curve

Get the latest business and tech insights delivered to your inbox daily.